NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 443,707 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the completion of the sale, the chief executive officer owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

NewAmsterdam Pharma Stock Down 7.4%

NASDAQ:NAMS traded down $2.63 during mid-day trading on Monday, reaching $32.83. 1,963,148 shares of the company were exchanged, compared to its average volume of 738,094. The stock has a market cap of $3.77 billion, a PE ratio of -18.98 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The company has a fifty day moving average of $34.06 and a 200 day moving average of $33.06.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. On average, equities research analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

NAMS has been the topic of several recent research reports. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Guggenheim lifted their price target on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Wall Street Zen lowered shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.55.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently made changes to their positions in NAMS. Frazier Life Sciences Management L.P. lifted its holdings in shares of NewAmsterdam Pharma by 1.4% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 16,943,774 shares of the company’s stock valued at $594,388,000 after purchasing an additional 241,818 shares in the last quarter. Capital World Investors raised its position in NewAmsterdam Pharma by 1.6% in the 4th quarter. Capital World Investors now owns 9,984,000 shares of the company’s stock valued at $350,239,000 after buying an additional 161,289 shares during the last quarter. Jennison Associates LLC lifted its stake in NewAmsterdam Pharma by 42.5% in the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares in the last quarter. Wellington Management Group LLP lifted its stake in NewAmsterdam Pharma by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after acquiring an additional 697,129 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.